AAAAAA

   
Results: 1-20 |
Results: 20
PHASE-I TRIAL OF SUBCUTANEOUS RECOMBINANT HUMAN INTERLEUKIN-12 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
Authors: MOTZER RJ RAKHIT A SCHWARTZ LH OLENCKI T MALONE TM SANDSTROM K NADEAU R PARMAR H BUKOWSKI R
Citation: Rj. Motzer et al., PHASE-I TRIAL OF SUBCUTANEOUS RECOMBINANT HUMAN INTERLEUKIN-12 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Clinical cancer research, 4(5), 1998, pp. 1183-1191
PHASE-I TRIAL OF SUBCUTANEOUS RECOMBINANT HUMAN INTERLEUKIN-12 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
Authors: MOTZER RJ RAKHIT A SCHWARTZ LH OLENCKI T MALONE TM SANDSTROM K NADEAU R PARMAR H BUKOWSKI R
Citation: Rj. Motzer et al., PHASE-I TRIAL OF SUBCUTANEOUS RECOMBINANT HUMAN INTERLEUKIN-12 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Clinical cancer research, 4(5), 1998, pp. 1183-1191
SIGNAL-TRANSDUCTION ABNORMALITIES IN T-LYMPHOCYTES FROM PATIENTS WITHADVANCED RENAL-CARCINOMA - CLINICAL RELEVANCE AND EFFECTS OF CYTOKINETHERAPY
Authors: BUKOWSKI RM RAYMAN P UZZO R BLOOM T SANDSTROM K PEEREBOOM D OLENCKI T BUDD GT MCLAIN D ELSON P NOVICK A FINKE JH
Citation: Rm. Bukowski et al., SIGNAL-TRANSDUCTION ABNORMALITIES IN T-LYMPHOCYTES FROM PATIENTS WITHADVANCED RENAL-CARCINOMA - CLINICAL RELEVANCE AND EFFECTS OF CYTOKINETHERAPY, Clinical cancer research, 4(10), 1998, pp. 2337-2347
PHASE-I TRIAL OF CAPECITABINE AND SUBCUTANEOUS INTERFERON-ALPHA IN RENAL-CELL CARCINOMA (RCC)
Authors: BUKOWSKI RM OLENCKI T BOCOCK K BUDD GT PEEREBOOM D MCLAIN D GRIFFIN T
Citation: Rm. Bukowski et al., PHASE-I TRIAL OF CAPECITABINE AND SUBCUTANEOUS INTERFERON-ALPHA IN RENAL-CELL CARCINOMA (RCC), Annals of oncology, 9, 1998, pp. 458-458
SHOULD CONTINENT DIVERSION BE PERFORMED IN PATIENTS WITH LOCALLY ADVANCED BLADDER-CANCER
Authors: WARD AM OLENCKI T PEERBOOM D KLEIN EA
Citation: Am. Ward et al., SHOULD CONTINENT DIVERSION BE PERFORMED IN PATIENTS WITH LOCALLY ADVANCED BLADDER-CANCER, Urology, 51(2), 1998, pp. 232-236
PHASE-I TRIAL OF ADOPTIVE IMMUNOTHERAPY FOR METASTATIC RENAL-CELL CARCINOMA WITH ACTIVATED LYMPH-NODE T-LYMPHOCYTES
Authors: PIENKNY AJ NOVICK AC PLAUTZ GE OLENCKI T SANDSTROM K BUKOWSKI RM SHU S
Citation: Aj. Pienkny et al., PHASE-I TRIAL OF ADOPTIVE IMMUNOTHERAPY FOR METASTATIC RENAL-CELL CARCINOMA WITH ACTIVATED LYMPH-NODE T-LYMPHOCYTES, The Journal of urology, 159(5), 1998, pp. 654-654
PHASE-II TRIAL OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN PATIENTS WITHRENAL-CELL CARCINOMA - CLINICAL-RESULTS AND IMMUNOLOGICAL CORRELATES OF RESPONSE
Authors: BUKOWSKI RM OLENCKI T WANG Q PEEREBOOM D BUDD GT ELSON P SANDSTROM K TUASON L RAYMAN P TUBBS R MCLAIN D KLEIN E NOVICK A FINKE J
Citation: Rm. Bukowski et al., PHASE-II TRIAL OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN PATIENTS WITHRENAL-CELL CARCINOMA - CLINICAL-RESULTS AND IMMUNOLOGICAL CORRELATES OF RESPONSE, Journal of immunotherapy with emphasis on tumor immunology, 20(4), 1997, pp. 301-311
RANDOMIZED TRIAL OF CARBOPLATIN PLUS AMIFOSTINE VERSUS CARBOPLATIN ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: BUDD GT GANAPATHI R ADELSTEIN DJ PELLEY R OLENCKI T PETRUS J MCLAIN D ZHANG JL CAPIZZI R BUKOWSKI RM
Citation: Gt. Budd et al., RANDOMIZED TRIAL OF CARBOPLATIN PLUS AMIFOSTINE VERSUS CARBOPLATIN ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS, Cancer, 80(6), 1997, pp. 1134-1140
PHASE-I TRIAL OF SUBCUTANEOUS INTERLEUKIN-3 IN PATIENTS WITH REFRACTORY MALIGNANCY - HEMATOLOGICAL, IMMUNOLOGICAL, AND PHARMACODYNAMIC FINDINGS
Authors: BUKOWSKI RM OLENCKI T GUNN H MCLAIN D BUDD GT SANDSTROM K TUASON L REDOVAN C RAYMAN P TUBBS R RESTA D ELSON P FINKE J
Citation: Rm. Bukowski et al., PHASE-I TRIAL OF SUBCUTANEOUS INTERLEUKIN-3 IN PATIENTS WITH REFRACTORY MALIGNANCY - HEMATOLOGICAL, IMMUNOLOGICAL, AND PHARMACODYNAMIC FINDINGS, Clinical cancer research, 2(2), 1996, pp. 347-357
IMMUNOMODULATORY EFFECTS OF INTERLEUKIN-2 AND INTERLEUKIN-4 IN PATIENTS WITH MALIGNANCY
Authors: OLENCKI T FINKE J TUBBS R TUASON L GREENE T MCLAIN D SWANSON SJ HERZOG P STANLEY T EDINGER M BUDD GT BUKOWSKI RM
Citation: T. Olencki et al., IMMUNOMODULATORY EFFECTS OF INTERLEUKIN-2 AND INTERLEUKIN-4 IN PATIENTS WITH MALIGNANCY, Journal of immunotherapy with emphasis on tumor immunology, 19(1), 1996, pp. 69-80
PHASE-II TRIAL OF SUBCUTANEOUSLY ADMINISTERED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: WOS E OLENCKI T TUASON L BUDD GT PEEREBOOM D SANDSTROM K MCLAIN D FINKE J BUKOWSKI RM
Citation: E. Wos et al., PHASE-II TRIAL OF SUBCUTANEOUSLY ADMINISTERED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, Cancer, 77(6), 1996, pp. 1149-1153
INDUCTION OF THE CXC CHEMOKINES IP-10 AND MIG IN PATIENTS (PTS) RECEIVING RHUIL-12 OR RIL-2
Authors: BUKOWSKI RM DON W REDOVAN C MCLAIN D SANDSTROM K OLENCKI T BUDD GT PEEREBOOM D GRIFFIN T TANNENBAUM C FINKE JK
Citation: Rm. Bukowski et al., INDUCTION OF THE CXC CHEMOKINES IP-10 AND MIG IN PATIENTS (PTS) RECEIVING RHUIL-12 OR RIL-2, Blood, 88(10), 1996, pp. 1247-1247
SELECTIVE CYTOKINE GENE-EXPRESSION IN RENAL-CELL CARCINOMA TUMOR-CELLS AND TUMOR-INFILTRATING LYMPHOCYTES
Authors: WANG Q REDOVAN C TUBBS R OLENCKI T KLEIN E KUDOH S FINKE J BUKOWSKI RM
Citation: Q. Wang et al., SELECTIVE CYTOKINE GENE-EXPRESSION IN RENAL-CELL CARCINOMA TUMOR-CELLS AND TUMOR-INFILTRATING LYMPHOCYTES, International journal of cancer, 61(6), 1995, pp. 780-785
INTERLEUKIN-6 - POTENTIAL CLINICAL-APPLICATIONS IN CANCER-THERAPY
Authors: OLENCKI T FINKE J BUKOWSKI RM
Citation: T. Olencki et al., INTERLEUKIN-6 - POTENTIAL CLINICAL-APPLICATIONS IN CANCER-THERAPY, CLINICAL IMMUNOTHERAPEUTICS, 2(4), 1994, pp. 278-294
PHASE-I TRIAL OF CISPLATIN, WR-2721, AND THE MURINE MONOCLONAL-ANTIBODY R24 IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND BIOLOGIC EFFECTS
Authors: BUKOWSKI RM MURTHY SA FINKE J CAULFIELD MJ TUBBS R HERZOG P STANLEY J EDINGER M TUASON L MCLAIN D BUDD GT OLENCKI T GANAPATHI R
Citation: Rm. Bukowski et al., PHASE-I TRIAL OF CISPLATIN, WR-2721, AND THE MURINE MONOCLONAL-ANTIBODY R24 IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND BIOLOGIC EFFECTS, Journal of immunotherapy with emphasis on tumor immunology, 15(4), 1994, pp. 273-282
PLEIOTROPIC EFFECTS OF CYTOKINES - CLINICAL AND PRECLINICAL STUDIES
Authors: BUKOWSKI RM OLENCKI T MCLAIN D FINKE JH
Citation: Rm. Bukowski et al., PLEIOTROPIC EFFECTS OF CYTOKINES - CLINICAL AND PRECLINICAL STUDIES, Stem cells, 12, 1994, pp. 129-141
AMIFOSTINE - POTENTIAL FOR CLINICALLY USEFUL CYTOPROTECTION
Authors: BUDD GT LORENZI V GANAPATHI R ADELSTEIN D PELLEY R OLENCKI T MCLAIN D BUKOWSKI RM
Citation: Gt. Budd et al., AMIFOSTINE - POTENTIAL FOR CLINICALLY USEFUL CYTOPROTECTION, Supportive care in cancer, 2(6), 1994, pp. 380-384
PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT INTERLEUKIN-3 (RHIL-3) FOLLOWING SUBCUTANEOUS (SQ) ADMINISTRATION TO PATIENTS WITH REFRACTORY MALIGNANCIES
Authors: BUKOWSKI RM OLENCKI T MCLAIN D TUASON L BUDD GT SANDSTROM K RAYMAN P GUNN H LEVITT D FINKE J
Citation: Rm. Bukowski et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT INTERLEUKIN-3 (RHIL-3) FOLLOWING SUBCUTANEOUS (SQ) ADMINISTRATION TO PATIENTS WITH REFRACTORY MALIGNANCIES, Blood, 84(10), 1994, pp. 10000580-10000580
HEMATOLOGIC EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHUGM-CSF) AND INTERLEUKIN-6 (RHIL-6) ADMINISTERED TO PATIENTS WITH MALIGNANCY
Authors: WOS E OLENCKI T BUDD GT PEEREBOOM D FINKE J WOOD L MCLAIN D TUBBS R REDOVAN C EDINGER M LEVITT D BUKOWSKI RM
Citation: E. Wos et al., HEMATOLOGIC EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHUGM-CSF) AND INTERLEUKIN-6 (RHIL-6) ADMINISTERED TO PATIENTS WITH MALIGNANCY, Blood, 84(10), 1994, pp. 10000598-10000598
CYTOKINE GENE-EXPRESSION AND SECRETION - EFFECTS OF RHIL-6 IN CANCER-PATIENTS
Authors: OLENCKI T BUDD GT MURTHY S FINKE J HERZOG P MCLAIN D TUBBS R TUASON L EDINGER M LEVITT D BUKOWSKI RM
Citation: T. Olencki et al., CYTOKINE GENE-EXPRESSION AND SECRETION - EFFECTS OF RHIL-6 IN CANCER-PATIENTS, Blood, 82(10), 1993, pp. 10000519-10000519
Risultati: 1-20 |